Article Summary With the FDA declaring the end of tirzepatide and semaglutide shortages by October 2024 and February 2025, commercial availability is now stabilized
Weve offered access to personalized medicine through compounding for nearly 6 years as a way to help providers individualize care to meet customer needs
A new study suggests that individuals taking popular new GLP-1 receptor agonist drugs, such as Ozempic, Wegovy and Mounjaro, face an increased risk of nausea, vomiting and other stomach problems, especially when taking higher doses of the medication
Mann JFE, Orsted DD, Brown-Frandsen K, et al
Adjusted sales in the U.S
What is the main difference between IGF-1 LR3 and HGH